{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:19:04Z","timestamp":1772119144229,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T00:00:00Z","timestamp":1471564800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bart\u2019s and the London National Institute of Health Research Cardiovascular Biomedical Research Unit"},{"name":"FUNDACAO PARA A CIENCIA E TECNOLOGIA, Portugal"},{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["15\/0005154"],"award-info":[{"award-number":["15\/0005154"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000382","name":"Society for Endocrinology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00125-016-4076-3","type":"journal-article","created":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T01:04:52Z","timestamp":1471568692000},"page":"2477-2486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment"],"prefix":"10.1007","volume":"59","author":[{"given":"Julius","family":"Kieswich","sequence":"first","affiliation":[]},{"given":"Sophie R.","family":"Sayers","sequence":"additional","affiliation":[]},{"given":"Marta F.","family":"Silvestre","sequence":"additional","affiliation":[]},{"given":"Steven M.","family":"Harwood","sequence":"additional","affiliation":[]},{"given":"Muhammad M.","family":"Yaqoob","sequence":"additional","affiliation":[]},{"given":"Paul W.","family":"Caton","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,8,19]]},"reference":[{"key":"4076_CR1","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1210\/jc.2011-0246","volume":"96","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Abdul-Ghani MA (2011) Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 96:2354\u20132366","journal-title":"J Clin Endocrinol Metab"},{"key":"4076_CR2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/dmrr.1201","volume":"27","author":"YH Chang","year":"2011","unstructured":"Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ (2011) Visfatin in overweight\/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 27:515\u2013527","journal-title":"Diabetes Metab Res Rev"},{"key":"4076_CR3","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.2337\/db06-0259","volume":"55","author":"A Lopez-Bermejo","year":"2006","unstructured":"Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al (2006) Serum visfatin increases with progressive beta-cell deterioration. Diabetes 55:2871\u20132875","journal-title":"Diabetes"},{"key":"4076_CR4","doi-asserted-by":"crossref","unstructured":"Yoshino J, Mills KF, Yoon MJ, Imai S (2011) Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 14:528\u2013536","DOI":"10.1016\/j.cmet.2011.08.014"},{"key":"4076_CR5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmet.2007.09.003","volume":"6","author":"JR Revollo","year":"2007","unstructured":"Revollo JR, Korner A, Mills KF et al (2007) Nampt\/PBEF\/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6:363\u2013375","journal-title":"Cell Metab"},{"key":"4076_CR6","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00125-011-2288-0","volume":"54","author":"PW Caton","year":"2011","unstructured":"Caton PW, Kieswich J, Yaqoob MM, Holness MJ, Sugden MC (2011) Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function. Diabetologia 54:3083\u20133092","journal-title":"Diabetologia"},{"key":"4076_CR7","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s00125-013-2851-y","volume":"56","author":"PW Caton","year":"2013","unstructured":"Caton PW, Richardson SJ, Kieswich J et al (2013) Sirtuin 3 regulates mouse pancreatic beta cell function and is suppressed in pancreatic islets isolated from human type 2 diabetic patients. Diabetologia 56:1068\u20131077","journal-title":"Diabetologia"},{"key":"4076_CR8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/138161209787185814","volume":"15","author":"S Imai","year":"2009","unstructured":"Imai S (2009) Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des 15:20\u201328","journal-title":"Curr Pharm Des"},{"key":"4076_CR9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1128\/MCB.14.2.1431","volume":"14","author":"B Samal","year":"1994","unstructured":"Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1994) Cloning and characterization of the cDNA encoding a novel human pre-B cell colony-enhancing factor. Mol Cell Biol 14:1431\u20131437","journal-title":"Mol Cell Biol"},{"key":"4076_CR10","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.4049\/jimmunol.178.3.1748","volume":"178","author":"AR Moschen","year":"2007","unstructured":"Moschen AR, Kaser A, Enrich B et al (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748\u20131758","journal-title":"J Immunol"},{"key":"4076_CR11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.1097243","volume":"307","author":"A Fukuhara","year":"2005","unstructured":"Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426\u2013430","journal-title":"Science"},{"key":"4076_CR12","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L","volume":"32","author":"A Rongvaux","year":"2002","unstructured":"Rongvaux A, Shea RJ, Mulks MH et al (2002) Pre-B cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32:3225\u20133234","journal-title":"Eur J Immunol"},{"key":"4076_CR13","first-page":"705","volume":"21","author":"MJ Yoon","year":"2015","unstructured":"Yoon MJ, Yoshida M, Johnson S et al (2015) SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD and function in mice. Cell Metab 21:705\u2013717","journal-title":"Cell Metab"},{"key":"4076_CR14","volume":"6","author":"N Hara","year":"2011","unstructured":"Hara N, Yamada K, Shibata T, Osago H, Tsuchiya M (2011) Nicotinamide phosphoribosyltransferase\/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS One 6:e22781","journal-title":"PLoS One"},{"key":"4076_CR15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nsmb1114","volume":"13","author":"T Wang","year":"2006","unstructured":"Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C (2006) Structure of Nampt\/PBEF\/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol 13:661\u2013662","journal-title":"Nat Struct Mol Biol"},{"key":"4076_CR16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.bcp.2009.02.017","volume":"77","author":"L Formentini","year":"2009","unstructured":"Formentini L, Moroni F, Chiarugi A (2009) Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 77:1612\u20131620","journal-title":"Biochem Pharmacol"},{"key":"4076_CR17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/JOE-09-0345","volume":"205","author":"PW Caton","year":"2010","unstructured":"Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R (2010) Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol 205:97\u2013106","journal-title":"J Endocrinol"},{"key":"4076_CR18","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","volume":"112","author":"SP Weisberg","year":"2003","unstructured":"Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796\u20131808","journal-title":"J Clin Invest"},{"key":"4076_CR19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","volume":"59","author":"AL Birkenfeld","year":"2014","unstructured":"Birkenfeld AL, Shulman GI (2014) Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59:713\u2013723","journal-title":"Hepatology"},{"key":"4076_CR20","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2174\/138161210791208947","volume":"16","author":"AR Moschen","year":"2010","unstructured":"Moschen AR, Gerner RR, Tilg H (2010) Pre-B cell colony enhancing factor\/NAMPT\/visfatin in inflammation and obesity-related disorders. Curr Pharm Des 16:1913\u20131920","journal-title":"Curr Pharm Des"},{"key":"4076_CR21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","volume":"11","author":"MY Donath","year":"2011","unstructured":"Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98\u2013107","journal-title":"Nat Rev Immunol"},{"key":"4076_CR22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1210\/jc.2005-1475","volume":"91","author":"MP Chen","year":"2006","unstructured":"Chen MP, Chung FM, Chang DM et al (2006) Elevated plasma level of visfatin\/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295\u2013299","journal-title":"J Clin Endocrinol Metab"},{"key":"4076_CR23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.mpg.0000235749.50820.b3","volume":"43","author":"DG Haider","year":"2006","unstructured":"Haider DG, Holzer G, Schaller G et al (2006) The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 43:548\u2013549","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4076_CR24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1042\/CS20050363","volume":"110","author":"K Krzyzanowska","year":"2006","unstructured":"Krzyzanowska K, Krugluger W, Mittermayer F et al (2006) Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci 110:605\u2013609","journal-title":"Clin Sci"},{"key":"4076_CR25","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1210\/jc.2006-0361","volume":"91","author":"C Pagano","year":"2006","unstructured":"Pagano C, Pilon C, Olivieri M et al (2006) Reduced plasma visfatin\/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91:3165\u20133170","journal-title":"J Clin Endocrinol Metab"},{"key":"4076_CR26","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2337\/diabetes.54.10.2911","volume":"54","author":"J Berndt","year":"2005","unstructured":"Berndt J, Kloting N, Kralisch S et al (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911\u20132916","journal-title":"Diabetes"},{"key":"4076_CR27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cyto.2013.11.008","volume":"65","author":"S Kim da","year":"2014","unstructured":"da Kim S, Kang S, Moon NR, Park S (2014) Central visfatin potentiates glucose-stimulated insulin secretion and beta-cell mass without increasing serum visfatin levels in diabetic rats. Cytokine 65:159\u2013166","journal-title":"Cytokine"},{"key":"4076_CR28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/JME-10-0106","volume":"47","author":"Q Cheng","year":"2011","unstructured":"Cheng Q, Dong W, Qian L, Wu J, Peng Y (2011) Visfatin inhibits apoptosis of pancreatic beta-cell line, MIN6, via the mitogen-activated protein kinase\/phosphoinositide 3-kinase pathway. J Mol Endocrinol 47:13\u201321","journal-title":"J Mol Endocrinol"},{"key":"4076_CR29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1677\/JME-09-0071","volume":"44","author":"JE Brown","year":"2010","unstructured":"Brown JE, Onyango DJ, Ramanjaneya M et al (2010) Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 44:171\u2013178","journal-title":"J Mol Endocrinol"},{"key":"4076_CR30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00424-009-0752-1","volume":"459","author":"RC Oita","year":"2010","unstructured":"Oita RC, Ferdinando D, Wilson S, Bunce C, Mazzatti DJ (2010) Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt-and MAPK-independent, NFkB-dependent manner. Pflugers Arch 459:619\u2013630","journal-title":"Pflugers Arch"},{"key":"4076_CR31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1474-9726.2007.00355.x","volume":"7","author":"KM Ramsey","year":"2008","unstructured":"Ramsey KM, Mills KF, Satoh A, Imai S (2008) Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7:78\u201388","journal-title":"Aging Cell"},{"key":"4076_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054106","volume":"8","author":"R Spinnler","year":"2013","unstructured":"Spinnler R, Gorski T, Stolz K et al (2013) The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion. PLoS One 8:e54106","journal-title":"PLoS One"},{"key":"4076_CR33","doi-asserted-by":"crossref","first-page":"13135","DOI":"10.1038\/srep13135","volume":"5","author":"SM Camp","year":"2015","unstructured":"Camp SM, Ceco E, Evenoski CL et al (2015) Unique Toll-like receptor 4 activation by NAMPT\/PBEF induces NFkB signaling and inflammatory lung injury. Sci Rep 5:13135","journal-title":"Sci Rep"},{"key":"4076_CR34","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00125-010-2042-z","volume":"54","author":"D Friebe","year":"2011","unstructured":"Friebe D, Neef M, Kratzsch J et al (2011) Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)\/pre-B cell colony (PBEF)\/visfatin linking obesity and inflammation in humans. Diabetologia 54:1200\u20131211","journal-title":"Diabetologia"},{"key":"4076_CR35","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.106.665893","volume":"115","author":"TB Dahl","year":"2007","unstructured":"Dahl TB, Yndestad A, Skjelland M et al (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115:972\u2013980","journal-title":"Circulation"},{"key":"4076_CR36","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s00125-006-0173-z","volume":"49","author":"CA Curat","year":"2006","unstructured":"Curat CA, Wegner V, Sengenes C et al (2006) Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49:744\u2013747","journal-title":"Diabetologia"},{"key":"4076_CR37","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI45887","volume":"121","author":"K Sun","year":"2011","unstructured":"Sun K, Kusminski CM, Scherer PE (2011) Adipose tissue remodeling and obesity. J Clin Invest 121:2094\u20132101","journal-title":"J Clin Invest"},{"key":"4076_CR38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2125.2012.04297.x","volume":"76","author":"M Boni-Schnetzler","year":"2013","unstructured":"Boni-Schnetzler M, Donath MY (2013) How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes. Br J Clin Pharmacol 76:263\u2013268","journal-title":"Br J Clin Pharmacol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-016-4076-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-4076-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-4076-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T06:59:51Z","timestamp":1499756391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-016-4076-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,19]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["4076"],"URL":"https:\/\/doi.org\/10.1007\/s00125-016-4076-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726654842.793584720","asserted-by":"object"}]},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,19]]}}}